INM-755 Clinical Program

Cross-Section of Reconstructed Human Epidermis Models



Healthy Volunteer



EBS Patient with K14 Mutation

Study 755-101-HV

- 22 healthy adults
- Subjects will be randomized to receive
  - INM-755 high concentration (8 subjects)
  - INM-755 low concentration (8 subjects)
  - Cream base (no drug) (6 subjects)
- Applied daily (2 mg cream/cm^2 skin) over approximately 5% BSA on the back, rubbed gently into the skin, and covered with a semiocclusive dressing (e.g., Tegaderm®).
- Evaluations for local and systemic safety/tolerability, plasma drug concentration, skin drug concentration
- Started December 16, 2019; completion projected end of March 2020

Study 755-102-HV

- ~8 healthy adults
- 4 small suction blister wounds created on lower back for each subject; roofs of blisters removed
- 4 wounds randomized to treatments
  - INM-755 high concentration plus semiocclusive dressing
  - INM-755 low concentration plus semiocclusive dressing
  - Cream base (no drug) plus semiocclusive dressing
  - Untreated plus semiocclusive dressing
- Treatments daily for up to 14 days
- Creams applied to dressing at ~100 mg cream/cm^2 skin, then placed on wounds
- Evaluations for local safety/tolerability, and characterization of wound closure
- Projected start in May 2020

Study 755-201-EB

- First study in patients with EB
- Study design under development
- Treatment up to 28 days
- Projected global regulatory submissions in 4Q2020

InMed Pharmaceuticals